Biologic treatment for early intervention and cartilage repair.
DeNovo NT Graft – Advancing the Science of Cartilage Repair.

DeNovo NT Natural Tissue Graft is a juvenile cartilaginous allograft tissue intended to provide surgeons with an early-intervention option for the repair of articular cartilage in a wide range of anatomic focal cartilage defects. It offers a single-stage procedure with fibrin fixation that eliminates the need for harvesting a periosteal flap. With DeNovo NT Graft, Zimmer demonstrates its commitment to leadership in providing surgeons – and their patients – with a complete continuum of joint care.

Juvenile Cartilage Tissue

DeNovo NT Graft consists of scaffold-free living articular cartilage, displaying biochemical properties similar to those of articular cartilage found in young, healthy joints.

Cartilage Injury and Treatment

- Adult articular cartilage has limited capacity for self-repair.¹
- Untreated focal defects begin a cycle of cartilage breakdown, arthritic degeneration and ultimately, the need for joint replacement.

DeNovo NT Graft offers a simple alternative to focal cartilage defect treatment.
Clinical Experience

- Human clinical experience includes 6 years of implant history and greater than 7,000 grafts.
- *DeNovo* NT Graft has been used to treat focal defects in a wide range of anatomical applications, including:
  - Knee (i.e., condyle, trochlea, patella, tibial plateau)
  - Foot and ankle (i.e., talus, MPJ)
  - Elbow
  - Shoulder (i.e., humeral head, glenoid)
  - Hip (i.e., acetabulum, femoral head)
- Clinical trials in both the ankle and knee demonstrate significant improvement in patient reports of pain, function, and activity scores (KOOS, AOFAS, FAAM, and VAS Pain Scale)²⁴

Juvenile bovine cartilage has a significantly higher cell density than adult cartilage (p<0.05), and juvenile bovine chondrocytes have significantly higher proliferation rate than adult chondrocytes (Day 3, p<0.01).

Juvenile chondrocytes synthesize significantly greater amount of GAG than adult chondrocytes (p<0.05). ("GAG" is glycosaminoglycan, a naturally occurring carbohydrate found in cartilage that decreases inflammation and serves as the building blocks of new cartilage.)

Outcome scores in 25 knee patients 24 months following DeNovo NT Graft implant. Significant improvement over baseline is seen for pain, symptoms, functions and sports (p<0.05).

*Animal Study results are not necessarily predictive of human results.*
Comparing Cartilage Defect Repair Treatment Alternatives

<table>
<thead>
<tr>
<th>Defect Characteristics</th>
<th>Tissue Characteristics</th>
<th>Procedure Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DeNovo NT Graft</strong></td>
<td>Chondral defects up to 5 cm² (greater at surgeon’s discretion)</td>
<td>Juvenile (≤ 13 yrs) hyaline cartilage, risk of disease transmission</td>
</tr>
<tr>
<td><strong>Autologous Chondrocyte Implantation (ACI)</strong></td>
<td>Chondral femoral defects; routinely 5 to 10 cm²</td>
<td>Adult autologous chondrocytes</td>
</tr>
<tr>
<td>*<em>Bone Marrow Stimulation</em></td>
<td>Chondral; limited treatment area &lt; 2 cm²</td>
<td>No tissue implanted, fibrous repair tissue²/³</td>
</tr>
<tr>
<td><strong>Osteochondral Autograft</strong></td>
<td>Osteochondral; limited treatment area ≤ 2 cm²</td>
<td>Adult autologous tissue from non-weight bearing surface</td>
</tr>
<tr>
<td><strong>Osteochondral Allograft</strong></td>
<td>Osteochondral; large defects &gt; 2 cm²</td>
<td>Adult allograft tissue, risk of disease transmission, typical wait period for graft availability</td>
</tr>
<tr>
<td><strong>Micronized Cartilage Matrix (BioCartilage⁵)</strong></td>
<td>Chondral; limited treatment area &lt; 2 cm²</td>
<td>Dehydrated, micronized adult cartilage</td>
</tr>
</tbody>
</table>

* e.g., debridement, microfracture, chondroplasty, subchondral drilling, etc.

References: